Explore our company news, white papers, and upcoming events.

News, Insights

Application Note
Supporting nasal product R&D and clinical manufacturing at Renaissance

February 21, 2024

Renaissance Lakewood, LLC: Breathing excellence into nasal product R&D and clinical manufacturing

Offering the potential of fast action, increased bioavailability and an improved patient experience, delivery through the highly vascularized and immunogenic nasal mucosa is becoming an increasingly sought-after administration route. With the pharma industry progressively opting for intranasal drug delivery over oral or parenteral routes, the global nasal drug delivery technology market has steadily grown, reaching $19 billion in 2022 and growing to $30 Billion in 2030[1].

However, for pharma companies to realize the potential of nasal delivery and for their therapeutic to successfully reach patients, they must first navigate the challenges of research and development (R&D) and clinical manufacturing.

At Renaissance Lakewood, we leverage our history of reliably supporting R&D and clinical manufacturing of nasal products, applying the lessons learned to overcome difficulties and meet evolving project needs. From one state-of-the-art campus,

we provide a solid foundation from early development to seamlessly progress your nasal product toward the market and the patients who need it.

Click here to download the entire article
Stay in Touch

Subscribe to our Newsletter

"*" indicates required fields

By entering your personal information, you confirm that you are at least 18 years of age or older.